Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky

Biogen shares dropped approximately 6.4% in a single session after Phase 2 CELIA trial data for diranersen missed its primary endpoint -- wiping out billions in market value. NEW YORK, May 22, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ: BIIB) investors lost approximately 6.4% per share on...